Is Penicillin Plus Gentamicin Synergistic against Clinical Group B Streptococcus isolates?: An In vitro Study
Group B (GBS) is increasingly causing invasive infections in non-pregnant adults. Elderly patients and those with comorbidities are at increased risk. On the basis of previous studies focusing on neonatal infections, penicillin plus gentamicin is recommended for infective endocarditis (IE) and perip...
Gespeichert in:
| Veröffentlicht in: | Frontiers in microbiology Jg. 7; S. 1680 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Switzerland
Frontiers Media S.A
21.10.2016
|
| Schlagworte: | |
| ISSN: | 1664-302X, 1664-302X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Group B
(GBS) is increasingly causing invasive infections in non-pregnant adults. Elderly patients and those with comorbidities are at increased risk. On the basis of previous studies focusing on neonatal infections, penicillin plus gentamicin is recommended for infective endocarditis (IE) and periprosthetic joint infections (PJI) in adults. The purpose of this study was to investigate whether a synergism with penicillin and gentamicin is present in GBS isolates that caused IE and PJI. We used 5 GBS isolates, two clinical strains and three control strains, including one displaying high-level gentamicin resistance (HLGR). The results from the checkerboard and time-kill assays (TKAs) were compared. For TKAs, antibiotic concentrations for penicillin were 0.048 and 0.2 mg/L, and for gentamicin 4 mg/L or 12.5 mg/L. In the checkerboard assay, the median fractional inhibitory concentration indices (FICIs) of all isolates indicated indifference. TKAs for all isolates failed to demonstrate synergism with penicillin 0.048 or 0.2 mg/L, irrespective of gentamicin concentrations used. Rapid killing was seen with penicillin 0.048 mg/L plus either 4 mg/L or 12.5 mg/L gentamicin, from 2 h up to 8 h hours after antibiotic exposure. TKAs with penicillin 0.2 mg/L decreased the starting inoculum below the limit of quantification within 4-6 h, irrespective of the addition of gentamicin. Fast killing was seen with penicillin 0.2 mg/L plus 12.5 mg/L gentamicin within the first 2 h. Our
results indicate that the addition of gentamicin to penicillin contributes to faster killing at low penicillin concentrations, but only within the first few hours. Twenty-four hours after antibiotic exposure, PEN alone was bactericidal and synergism was not seen. |
|---|---|
| AbstractList | Group B Streptococcus (GBS) is increasingly causing invasive infections in non-pregnant adults. Elderly patients and those with comorbidities are at increased risk. On the basis of previous studies focusing on neonatal infections, penicillin plus gentamicin is recommended for infective endocarditis (IE) and periprosthetic joint infections (PJI) in adults. The purpose of this study was to investigate whether a synergism with penicillin and gentamicin is present in GBS isolates that caused IE and PJI. We used 5 GBS isolates, two clinical strains and three control strains, including one displaying high-level gentamicin resistance (HLGR). The results from the checkerboard and time-kill assays (TKAs) were compared. For TKAs, antibiotic concentrations for penicillin were 0.048 and 0.2 mg/L, and for gentamicin 4 mg/L or 12.5 mg/L. In the checkerboard assay, the median fractional inhibitory concentration indices (FICIs) of all isolates indicated indifference. TKAs for all isolates failed to demonstrate synergism with penicillin 0.048 or 0.2 mg/L, irrespective of gentamicin concentrations used. Rapid killing was seen with penicillin 0.048 mg/L plus either 4 mg/L or 12.5 mg/L gentamicin, from 2 h up to 8 h hours after antibiotic exposure. TKAs with penicillin 0.2 mg/L decreased the starting inoculum below the limit of quantification within 4–6 h, irrespective of the addition of gentamicin. Fast killing was seen with penicillin 0.2 mg/L plus 12.5 mg/L gentamicin within the first 2 h. Our in vitro results indicate that the addition of gentamicin to penicillin contributes to faster killing at low penicillin concentrations, but only within the first few hours. Twenty-four hours after antibiotic exposure, PEN alone was bactericidal and synergism was not seen. Group B Streptococcus (GBS) is increasingly causing invasive infections in nonpregnant adults. Elderly patients and those with comorbidities are at increased risk. On the basis of previous studies focusing on neonatal infections, penicillin plus gentamicin is recommended for infective endocarditis (IE) and periprosthetic joint infections (PJI) in adults. The purpose of this study was to investigate whether a synergism with penicillin and gentamicin is present in GBS isolates that caused IE and PJI. We used 5 GBS isolates, two clinical strains and three control strains, including one displaying high-level gentamicin resistance (HLGR). The results from the checkerboard and time-kill assays (TKAs) were compared. For TKAs, antibiotic concentrations for penicillin were 0.048 and 0.2 mg/L, and for gentamicin 4 mg/L or 12.5 mg/L. In the checkerboard assay, the median fractional inhibitory concentration indices (FICIs) of all isolates indicated indifference. TKAs for all isolates failed to demonstrate synergism with penicillin 0.048 or 0.2 mg/L, irrespective of gentamicin concentrations used. Rapid killing was seen with penicillin 0.048 mg/L plus either 4 mg/L or 12.5 mg/L gentamicin, from 2 h up to 8 h hours after antibiotic exposure. TKAs with penicillin 0.2 mg/L decreased the starting inoculum below the limit of quantification within 4 h to 6 h, irrespective of the addition of gentamicin. Fast killing was seen with penicillin 0.2 mg/L plus 12.5 mg/L gentamicin within the first 2 h. Our in vitro results indicate that the addition of gentamicin to penicillin contributes to faster killing at low penicillin concentrations, but only within the first few hours. Twenty-four hours after antibiotic exposure, PEN alone was bactericidal and synergism was not seen. Group B Streptococcus (GBS) is increasingly causing invasive infections in non-pregnant adults. Elderly patients and those with comorbidities are at increased risk. On the basis of previous studies focusing on neonatal infections, penicillin plus gentamicin is recommended for infective endocarditis (IE) and periprosthetic joint infections (PJI) in adults. The purpose of this study was to investigate whether a synergism with penicillin and gentamicin is present in GBS isolates that caused IE and PJI. We used 5 GBS isolates, two clinical strains and three control strains, including one displaying high-level gentamicin resistance (HLGR). The results from the checkerboard and time-kill assays (TKAs) were compared. For TKAs, antibiotic concentrations for penicillin were 0.048 and 0.2 mg/L, and for gentamicin 4 mg/L or 12.5 mg/L. In the checkerboard assay, the median fractional inhibitory concentration indices (FICIs) of all isolates indicated indifference. TKAs for all isolates failed to demonstrate synergism with penicillin 0.048 or 0.2 mg/L, irrespective of gentamicin concentrations used. Rapid killing was seen with penicillin 0.048 mg/L plus either 4 mg/L or 12.5 mg/L gentamicin, from 2 h up to 8 h hours after antibiotic exposure. TKAs with penicillin 0.2 mg/L decreased the starting inoculum below the limit of quantification within 4-6 h, irrespective of the addition of gentamicin. Fast killing was seen with penicillin 0.2 mg/L plus 12.5 mg/L gentamicin within the first 2 h. Our in vitro results indicate that the addition of gentamicin to penicillin contributes to faster killing at low penicillin concentrations, but only within the first few hours. Twenty-four hours after antibiotic exposure, PEN alone was bactericidal and synergism was not seen.Group B Streptococcus (GBS) is increasingly causing invasive infections in non-pregnant adults. Elderly patients and those with comorbidities are at increased risk. On the basis of previous studies focusing on neonatal infections, penicillin plus gentamicin is recommended for infective endocarditis (IE) and periprosthetic joint infections (PJI) in adults. The purpose of this study was to investigate whether a synergism with penicillin and gentamicin is present in GBS isolates that caused IE and PJI. We used 5 GBS isolates, two clinical strains and three control strains, including one displaying high-level gentamicin resistance (HLGR). The results from the checkerboard and time-kill assays (TKAs) were compared. For TKAs, antibiotic concentrations for penicillin were 0.048 and 0.2 mg/L, and for gentamicin 4 mg/L or 12.5 mg/L. In the checkerboard assay, the median fractional inhibitory concentration indices (FICIs) of all isolates indicated indifference. TKAs for all isolates failed to demonstrate synergism with penicillin 0.048 or 0.2 mg/L, irrespective of gentamicin concentrations used. Rapid killing was seen with penicillin 0.048 mg/L plus either 4 mg/L or 12.5 mg/L gentamicin, from 2 h up to 8 h hours after antibiotic exposure. TKAs with penicillin 0.2 mg/L decreased the starting inoculum below the limit of quantification within 4-6 h, irrespective of the addition of gentamicin. Fast killing was seen with penicillin 0.2 mg/L plus 12.5 mg/L gentamicin within the first 2 h. Our in vitro results indicate that the addition of gentamicin to penicillin contributes to faster killing at low penicillin concentrations, but only within the first few hours. Twenty-four hours after antibiotic exposure, PEN alone was bactericidal and synergism was not seen. Group B (GBS) is increasingly causing invasive infections in non-pregnant adults. Elderly patients and those with comorbidities are at increased risk. On the basis of previous studies focusing on neonatal infections, penicillin plus gentamicin is recommended for infective endocarditis (IE) and periprosthetic joint infections (PJI) in adults. The purpose of this study was to investigate whether a synergism with penicillin and gentamicin is present in GBS isolates that caused IE and PJI. We used 5 GBS isolates, two clinical strains and three control strains, including one displaying high-level gentamicin resistance (HLGR). The results from the checkerboard and time-kill assays (TKAs) were compared. For TKAs, antibiotic concentrations for penicillin were 0.048 and 0.2 mg/L, and for gentamicin 4 mg/L or 12.5 mg/L. In the checkerboard assay, the median fractional inhibitory concentration indices (FICIs) of all isolates indicated indifference. TKAs for all isolates failed to demonstrate synergism with penicillin 0.048 or 0.2 mg/L, irrespective of gentamicin concentrations used. Rapid killing was seen with penicillin 0.048 mg/L plus either 4 mg/L or 12.5 mg/L gentamicin, from 2 h up to 8 h hours after antibiotic exposure. TKAs with penicillin 0.2 mg/L decreased the starting inoculum below the limit of quantification within 4-6 h, irrespective of the addition of gentamicin. Fast killing was seen with penicillin 0.2 mg/L plus 12.5 mg/L gentamicin within the first 2 h. Our results indicate that the addition of gentamicin to penicillin contributes to faster killing at low penicillin concentrations, but only within the first few hours. Twenty-four hours after antibiotic exposure, PEN alone was bactericidal and synergism was not seen. |
| Author | Decosterd, Laurent Sendi, Parham Lupo, Agnese Ruppen, Corinne |
| AuthorAffiliation | 3 Division and Laboratory of Clinical Pharmacology, Service of Biomedicine, Department of Laboratories, Centre Hospitalier Universitaire Vaudois (CHUV) Lausanne, Switzerland 4 Department of Infectious Diseases, Bern University Hospital, University of Bern Bern, Switzerland 2 Graduate School for Cellular and Biomedical Sciences, University of Bern Bern, Switzerland 1 Institute for Infectious Diseases, University of Bern Bern, Switzerland |
| AuthorAffiliation_xml | – name: 3 Division and Laboratory of Clinical Pharmacology, Service of Biomedicine, Department of Laboratories, Centre Hospitalier Universitaire Vaudois (CHUV) Lausanne, Switzerland – name: 2 Graduate School for Cellular and Biomedical Sciences, University of Bern Bern, Switzerland – name: 1 Institute for Infectious Diseases, University of Bern Bern, Switzerland – name: 4 Department of Infectious Diseases, Bern University Hospital, University of Bern Bern, Switzerland |
| Author_xml | – sequence: 1 givenname: Corinne surname: Ruppen fullname: Ruppen, Corinne – sequence: 2 givenname: Agnese surname: Lupo fullname: Lupo, Agnese – sequence: 3 givenname: Laurent surname: Decosterd fullname: Decosterd, Laurent – sequence: 4 givenname: Parham surname: Sendi fullname: Sendi, Parham |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27818657$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kt1rUzEYxg8ycXPu3ivJpTetOclJcuKFMovWwsDBFLwL-awZaVKTnEH_e9N2jk0wkO_n_b35eF52JzFF23WvezjHeOTv3MZrNUewp_NWR_isO-spHWYYop8nj8an3UUpt7CVAaLWvuhOERv7kRJ21m1WBVzb6LUPwUdwHaYCljZW2eBtfrOLNq99qV4DuZY-lgoWTei1DGCZ07QFn8BNzXZbk05at2hfUpDVlo_vwWUEqwjufM2piSaze9U9dzIUe3Hfn3c_vnz-vvg6u_q2XC0ur2Z6oKjOBk3ZMLCBu5FR2zvXa8wwhkQRwiwnynDNJYQKc01H3FtlLUUUOkuMQdTh82515Jokb8U2-43MO5GkF4eFlNdC5nanYAUxTrFhdEoaM3DMFdNYYuSIZNwowhvrw5G1ndTGGt0eJ8vwBPp0J_pfYp3uBIEMEzQ2wNt7QE6_J1uq2PiibQgy2jQV0Y-YQcQ4ok365nGuhyR__6sJ4FGgcyolW_cg6aHYu0IcXCH2rhAHV7QQ-k-I9lVWn_an9eH_gX8ASBa-wQ |
| CitedBy_id | crossref_primary_10_1080_1120009X_2020_1838830 crossref_primary_10_3390_molecules25153522 crossref_primary_10_1080_1040841X_2020_1758626 crossref_primary_10_1093_jac_dkx207 crossref_primary_10_3390_antibiotics11070960 crossref_primary_10_1007_s10096_018_03446_2 crossref_primary_10_1177_1120700021991467 crossref_primary_10_1016_j_jgar_2017_07_005 crossref_primary_10_1080_23744235_2016_1244612 crossref_primary_10_1038_s41598_020_79354_3 crossref_primary_10_1089_mdr_2021_0071 crossref_primary_10_3389_fmicb_2018_00919 |
| Cites_doi | 10.1080/00365540701534517 10.1016/S0167-7799(98)01229-3 10.1128/AAC.01933-15 10.1093/infdis/155.6.1233 10.7164/antibiotics.30.513 10.1128/CMR.00047-06 10.1056/NEJMra040181 10.1086/381972 10.1128/CMR.3.3.269 10.1016/j.mimet.2009.11.010 10.1007/BF02386230 10.1201/b13787-4 10.1542/peds.2012-0541 10.1128/AAC.26.2.220 10.1128/AAC.39.3.650 10.1128/JCM.00369-11 10.1128/JCM.41.6.2530-2536.2003 10.1086/516266 10.1093/infdis/144.5.411 10.1128/AAC.37.3.613 10.1056/NEJMoa020205 10.1128/AAC.15.3.484 10.1046/j.1365-2958.2002.03126.x 10.1093/infdis/152.3.515 10.1093/clinids/11.3.361 10.1093/eurheartj/ehp285 10.1086/599369 10.1016/S1367-5931(99)00025-3 10.1128/AAC.22.5.743 10.1001/jama.299.17.2056 10.1128/AAC.19.5.716 10.2165/0003088-200948020-00002 |
| ContentType | Journal Article |
| Copyright | Copyright © 2016 Ruppen, Lupo, Decosterd and Sendi. 2016 Ruppen, Lupo, Decosterd and Sendi |
| Copyright_xml | – notice: Copyright © 2016 Ruppen, Lupo, Decosterd and Sendi. 2016 Ruppen, Lupo, Decosterd and Sendi |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fmicb.2016.01680 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-302X |
| ExternalDocumentID | oai_doaj_org_article_5dfb748fbadd4939b7c3a32f5a79db59 PMC5073528 27818657 10_3389_fmicb_2016_01680 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Velux Stiftung grantid: 724 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK ECGQY GROUPED_DOAJ GX1 HYE IPNFZ KQ8 M48 M~E O5R O5S OK1 PGMZT RIG RNS RPM ACXDI IAO IEA IHR NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-4c6744749f876e1ff1c373305b557e95bd9c9a00b39c6831ebee6260fe5dd26f3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 13 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000388563000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-302X |
| IngestDate | Fri Oct 03 12:29:11 EDT 2025 Tue Sep 30 16:28:40 EDT 2025 Sun Nov 09 14:00:25 EST 2025 Tue Oct 15 23:57:24 EDT 2024 Sat Nov 29 06:02:43 EST 2025 Tue Nov 18 22:02:34 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | gentamicin synergism aminoglycosides Streptococcus agalactiae Group B Streptococcus |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-4c6744749f876e1ff1c373305b557e95bd9c9a00b39c6831ebee6260fe5dd26f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Rodrigo Reyes, McGill University, Canada; Francisco Dionisio, University of Lisbon, Portugal Edited by: Marcelo Tolmasky, California State University, Fullerton, USA This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology |
| OpenAccessLink | https://doaj.org/article/5dfb748fbadd4939b7c3a32f5a79db59 |
| PMID | 27818657 |
| PQID | 1837027926 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5dfb748fbadd4939b7c3a32f5a79db59 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5073528 proquest_miscellaneous_1837027926 pubmed_primary_27818657 crossref_primary_10_3389_fmicb_2016_01680 crossref_citationtrail_10_3389_fmicb_2016_01680 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-10-21 |
| PublicationDateYYYYMMDD | 2016-10-21 |
| PublicationDate_xml | – month: 10 year: 2016 text: 2016-10-21 day: 21 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in microbiology |
| PublicationTitleAlternate | Front Microbiol |
| PublicationYear | 2016 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Geddes (B7) 2010 Imperi (B13) 2010; 80 Polin (B28) 2012; 129 Pankey (B23) 2004; 38 Plaut (B27) 1969; 74 Swingle (B36) 1985; 152 Hallander (B11) 1982; 22 McCafferty (B18) 1999; 3 Bayer (B4) 1984; 26 Kim (B15) 1987; 155 Amsterdam (B1) 2005 Landersdorfer (B17) 2009; 48 Moody (B20) 2010 Turnidge (B37) 2007; 20 Overturf (B22) 1977; 30 Ruppen (B31) 2015 Sutton (B35) 2011; 17 Habib (B10) 2009; 30 van der Beek (B38) 1984; 50 Moody (B19) 2010 Glaser (B8) 2002; 45 Kim (B16) 1981; 144 Zimmerli (B41) 2004; 351 Hindler (B12) 2010 Brook (B5) 1989; 11 Pillai (B26) 2005 Yagupsky (B40) 1990; 3 Penalva (B24) 1998; 16 Schrag (B32) 2002; 347 Phares (B25) 2008; 299 Cooper (B6) 1979; 15 Baddour (B2) 1998; 26 Sendi (B33) 2016; 60 Nicolau (B21) 1995; 39 Puttaswamy (B29) 2011; 49 Baker (B3) 1981; 19 Gonzalez (B9) 1998; 58 Westling (B39) 2007; 39 Rand (B30) 1993; 37 Skoff (B34) 2009; 49 Jones (B14) 2003; 41 7181485 - Antimicrob Agents Chemother. 1982 Nov;22(5):743-52 12354221 - Mol Microbiol. 2002 Sep;45(6):1499-513 7031141 - J Infect Dis. 1981 Nov;144(5):411-9 26729498 - Antimicrob Agents Chemother. 2016 Jan 04;60(3):1702-7 12791877 - J Clin Microbiol. 2003 Jun;41(6):2530-6 3553349 - J Infect Dis. 1987 Jun;155(6):1233-41 328471 - J Antibiot (Tokyo). 1977 Jun;30(6):513-8 10600730 - Curr Opin Chem Biol. 1999 Dec;3(6):672-80 15483283 - N Engl J Med. 2004 Oct 14;351(16):1645-54 2664999 - Rev Infect Dis. 1989 May-Jun;11(3):361-8 9835856 - Am Fam Physician. 1998 Nov 15;58(8):1811-20 18027277 - Scand J Infect Dis. 2007;39(11-12):929-46 22547779 - Pediatrics. 2012 May;129(5):1006-15 6567464 - Antimicrob Agents Chemother. 1984 Aug;26(2):220-3 19958797 - J Microbiol Methods. 2010 Feb;80(2):212-4 17630331 - Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents 9455511 - Clin Infect Dis. 1998 Jan;26(1):66-71 19271782 - Clin Pharmacokinet. 2009;48(2):89-124 12140298 - N Engl J Med. 2002 Jul 25;347(4):233-9 7793867 - Antimicrob Agents Chemother. 1995 Mar;39(3):650-5 7027921 - Antimicrob Agents Chemother. 1981 May;19(5):716-25 2200606 - Clin Microbiol Rev. 1990 Jul;3(3):269-79 19480572 - Clin Infect Dis. 2009 Jul 1;49(1):85-92 3897398 - J Infect Dis. 1985 Sep;152(3):515-20 380461 - Antimicrob Agents Chemother. 1979 Mar;15(3):484-6 6442122 - Antonie Van Leeuwenhoek. 1984;50(5-6):625-39 9830157 - Trends Biotechnol. 1998 Nov;16(11):483-9 21471337 - J Clin Microbiol. 2011 Jun;49(6):2286-9 8460929 - Antimicrob Agents Chemother. 1993 Mar;37(3):613-5 19713420 - Eur Heart J. 2009 Oct;30(19):2369-413 18460666 - JAMA. 2008 May 7;299(17):2056-65 5789569 - J Lab Clin Med. 1969 Jul;74(1):12-8 14999632 - Clin Infect Dis. 2004 Mar 15;38(6):864-70 |
| References_xml | – volume: 39 start-page: 929 year: 2007 ident: B39 article-title: Swedish guidelines for diagnosis and treatment of infective endocarditis. publication-title: Scand. J. Infect. Dis. doi: 10.1080/00365540701534517 – volume: 16 start-page: 483 year: 1998 ident: B24 article-title: The optimization of penicillin biosynthesis in fungi. publication-title: Trends Biotechnol. doi: 10.1016/S0167-7799(98)01229-3 – volume: 60 start-page: 1702 year: 2016 ident: B33 article-title: Chromosomally and extrachromosomally mediated high-level gentamicin resistance in Streptococcus agalactiae. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01933-15 – volume: 155 start-page: 1233 year: 1987 ident: B15 article-title: Effect of antimicrobial therapy for experimental infections due to group B Streptococcus on mortality and clearance of bacteria. publication-title: J. Infect. Dis. doi: 10.1093/infdis/155.6.1233 – volume: 30 start-page: 513 year: 1977 ident: B22 article-title: Bactericidal studies of penicillin-gentamicin combinations against group B streptococci. publication-title: J. Antibiot. (Tokyo) doi: 10.7164/antibiotics.30.513 – start-page: 365 year: 2005 ident: B26 article-title: “Antimicrobial combinations,” in publication-title: Antibiotics in Laboratory Medicine – volume: 20 start-page: 391 year: 2007 ident: B37 article-title: Setting and revising antibacterial susceptibility breakpoints. publication-title: Clin. Microbiol. Rev. doi: 10.1128/CMR.00047-06 – volume: 351 start-page: 1645 year: 2004 ident: B41 article-title: Prosthetic-joint infections. publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra040181 – volume: 38 start-page: 864 year: 2004 ident: B23 article-title: Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. publication-title: Clin. Infect. Dis. doi: 10.1086/381972 – volume: 3 start-page: 269 year: 1990 ident: B40 article-title: Quantitative aspects of septicemia. publication-title: Clin. Microbiol. Rev. doi: 10.1128/CMR.3.3.269 – volume: 80 start-page: 212 year: 2010 ident: B13 article-title: A multiplex PCR assay for the direct identification of the capsular type (Ia to IX) of Streptococcus agalactiae. publication-title: J. Microbiol. Methods doi: 10.1016/j.mimet.2009.11.010 – volume: 50 start-page: 625 year: 1984 ident: B38 article-title: Penicillin production: biotechnology at its best. publication-title: Antonie Van Leeuwenhoek doi: 10.1007/BF02386230 – start-page: 5 year: 2010 ident: B7 article-title: “Benylpenicillin (Penicillin G),” in publication-title: Kucers’ the Use of Antibiotics doi: 10.1201/b13787-4 – volume: 58 start-page: 1811 year: 1998 ident: B9 article-title: Aminoglycosides: a practical review. publication-title: Am. Fam. Physician – volume: 129 start-page: 1006 year: 2012 ident: B28 article-title: Management of neonates with suspected or proven early-onset bacterial sepsis. publication-title: Pediatrics doi: 10.1542/peds.2012-0541 – volume: 26 start-page: 220 year: 1984 ident: B4 article-title: Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.26.2.220 – volume: 39 start-page: 650 year: 1995 ident: B21 article-title: Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.39.3.650 – volume: 49 start-page: 2286 year: 2011 ident: B29 article-title: Novel electrical method for early detection of viable bacteria in blood cultures. publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.00369-11 – volume: 74 start-page: 12 year: 1969 ident: B27 article-title: Penicillin handling in normal and azotemic patients. publication-title: J. Lab. Clin. Med. – volume: 41 start-page: 2530 year: 2003 ident: B14 article-title: Multilocus sequence typing system for group B Streptococcus. publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.41.6.2530-2536.2003 – volume: 26 start-page: 66 year: 1998 ident: B2 article-title: Infective endocarditis caused by beta-hemolytic streptococci. The infectious diseases society of America’s emerging infections network. publication-title: Clin. Infect. Dis. doi: 10.1086/516266 – year: 2015 ident: B31 publication-title: Time Kill Assays for Streptococcus agalactiae and Synergy Testing. Protocol Exchange [Online]. – volume: 144 start-page: 411 year: 1981 ident: B16 article-title: Penicillin tolerance in group B streptococci isolated from infected neonates. publication-title: J. Infect. Dis. doi: 10.1093/infdis/144.5.411 – start-page: 5.10.11.11 year: 2010 ident: B20 article-title: “Tests to assess bactericidal activity,” in publication-title: Clinical Microbiology Procedures Handbook – volume: 37 start-page: 613 year: 1993 ident: B30 article-title: Reproducibility of the microdilution checkerboard method for antibiotic synergy. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.37.3.613 – volume: 347 start-page: 233 year: 2002 ident: B32 article-title: A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa020205 – start-page: 61 year: 2005 ident: B1 article-title: “Susceptibility testing of antimicrobials in liquid media,” in publication-title: Antibiotics in Laboratory Medicine – volume: 15 start-page: 484 year: 1979 ident: B6 article-title: Synergistic effects of ampicillin-aminoglycoside combinations on group B Streptococci. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.15.3.484 – volume: 45 start-page: 1499 year: 2002 ident: B8 article-title: Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. publication-title: Mol. Microbiol. doi: 10.1046/j.1365-2958.2002.03126.x – start-page: 5.2.1 year: 2010 ident: B12 article-title: “Broth microdilution MIC test,” in publication-title: Clinical Microbiology Procedures Handbook – start-page: 5.12.11 year: 2010 ident: B19 article-title: “Synergism testing: broth microdilution checkerboard and broth macrodilution methods,” in publication-title: Clinical Microbiology Procedures Handbook – volume: 152 start-page: 515 year: 1985 ident: B36 article-title: Synergy between penicillins and low concentrations of gentamicin in the killing of group B streptococci. publication-title: J. Infect. Dis. doi: 10.1093/infdis/152.3.515 – volume: 11 start-page: 361 year: 1989 ident: B5 article-title: Inoculum effect. publication-title: Rev. Infect. Dis. doi: 10.1093/clinids/11.3.361 – volume: 30 start-page: 2369 year: 2009 ident: B10 article-title: Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehp285 – volume: 49 start-page: 85 year: 2009 ident: B34 article-title: Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. publication-title: Clin. Infect. Dis. doi: 10.1086/599369 – volume: 3 start-page: 672 year: 1999 ident: B18 article-title: Synergy and duality in peptide antibiotic mechanisms. publication-title: Curr. Opin. Chem. Biol. doi: 10.1016/S1367-5931(99)00025-3 – volume: 22 start-page: 743 year: 1982 ident: B11 article-title: Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.22.5.743 – volume: 299 start-page: 2056 year: 2008 ident: B25 article-title: Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. publication-title: JAMA doi: 10.1001/jama.299.17.2056 – volume: 17 start-page: 42 year: 2011 ident: B35 article-title: Accuracy of plate counts. publication-title: J. Validation Tecnhol. – volume: 19 start-page: 716 year: 1981 ident: B3 article-title: Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.19.5.716 – volume: 48 start-page: 89 year: 2009 ident: B17 article-title: Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. publication-title: Clin. Pharmacokinet. doi: 10.2165/0003088-200948020-00002 – reference: 19958797 - J Microbiol Methods. 2010 Feb;80(2):212-4 – reference: 7181485 - Antimicrob Agents Chemother. 1982 Nov;22(5):743-52 – reference: 26729498 - Antimicrob Agents Chemother. 2016 Jan 04;60(3):1702-7 – reference: 21471337 - J Clin Microbiol. 2011 Jun;49(6):2286-9 – reference: 15483283 - N Engl J Med. 2004 Oct 14;351(16):1645-54 – reference: 18460666 - JAMA. 2008 May 7;299(17):2056-65 – reference: 12791877 - J Clin Microbiol. 2003 Jun;41(6):2530-6 – reference: 7027921 - Antimicrob Agents Chemother. 1981 May;19(5):716-25 – reference: 19713420 - Eur Heart J. 2009 Oct;30(19):2369-413 – reference: 6567464 - Antimicrob Agents Chemother. 1984 Aug;26(2):220-3 – reference: 12354221 - Mol Microbiol. 2002 Sep;45(6):1499-513 – reference: 17630331 - Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents – reference: 14999632 - Clin Infect Dis. 2004 Mar 15;38(6):864-70 – reference: 5789569 - J Lab Clin Med. 1969 Jul;74(1):12-8 – reference: 3553349 - J Infect Dis. 1987 Jun;155(6):1233-41 – reference: 380461 - Antimicrob Agents Chemother. 1979 Mar;15(3):484-6 – reference: 12140298 - N Engl J Med. 2002 Jul 25;347(4):233-9 – reference: 3897398 - J Infect Dis. 1985 Sep;152(3):515-20 – reference: 19271782 - Clin Pharmacokinet. 2009;48(2):89-124 – reference: 328471 - J Antibiot (Tokyo). 1977 Jun;30(6):513-8 – reference: 19480572 - Clin Infect Dis. 2009 Jul 1;49(1):85-92 – reference: 9830157 - Trends Biotechnol. 1998 Nov;16(11):483-9 – reference: 9455511 - Clin Infect Dis. 1998 Jan;26(1):66-71 – reference: 7031141 - J Infect Dis. 1981 Nov;144(5):411-9 – reference: 18027277 - Scand J Infect Dis. 2007;39(11-12):929-46 – reference: 2200606 - Clin Microbiol Rev. 1990 Jul;3(3):269-79 – reference: 22547779 - Pediatrics. 2012 May;129(5):1006-15 – reference: 9835856 - Am Fam Physician. 1998 Nov 15;58(8):1811-20 – reference: 8460929 - Antimicrob Agents Chemother. 1993 Mar;37(3):613-5 – reference: 6442122 - Antonie Van Leeuwenhoek. 1984;50(5-6):625-39 – reference: 10600730 - Curr Opin Chem Biol. 1999 Dec;3(6):672-80 – reference: 7793867 - Antimicrob Agents Chemother. 1995 Mar;39(3):650-5 – reference: 2664999 - Rev Infect Dis. 1989 May-Jun;11(3):361-8 |
| SSID | ssj0000402000 |
| Score | 2.200184 |
| Snippet | Group B
(GBS) is increasingly causing invasive infections in non-pregnant adults. Elderly patients and those with comorbidities are at increased risk. On the... Group B Streptococcus (GBS) is increasingly causing invasive infections in non-pregnant adults. Elderly patients and those with comorbidities are at increased... Group B Streptococcus (GBS) is increasingly causing invasive infections in nonpregnant adults. Elderly patients and those with comorbidities are at increased... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1680 |
| SubjectTerms | Aminoglycosides Gentamicin group B streptococcus Microbiology Streptococcus agalactiae Synergism |
| Title | Is Penicillin Plus Gentamicin Synergistic against Clinical Group B Streptococcus isolates?: An In vitro Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27818657 https://www.proquest.com/docview/1837027926 https://pubmed.ncbi.nlm.nih.gov/PMC5073528 https://doaj.org/article/5dfb748fbadd4939b7c3a32f5a79db59 |
| Volume | 7 |
| WOSCitedRecordID | wos000388563000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1664-302X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402000 issn: 1664-302X databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-302X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402000 issn: 1664-302X databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagAokL4k0KVEbiwiE0iV8xF9SiFpCgqgRIe7Nsxy6RluxqN1tpL_3tzDjpahchuHBIDomjWPPN2DP2-BtCXtVWOR4bnte2YTm3VZlbXsa80q4IopCWx4T0Z3V2Vk8m-nyr1BfmhA30wIPgDkUTneJ1dGCIXDPtlGeWVVFYpRsn0tE98Hq2gqk0BmNYVBTDviREYRpgar3DVC75Bi5kgdyahxJd_598zN9TJbfmntN75O7oNNKjobP3yY3QPSC3hzKS64dk-mlJz0PXelw76eh8ulrSD5gT_hO3zenXNZ7vS4TM1F7YFhxCOtKBTmlae6LHFHen5_0MhkcPX7egkeiEvntLj2jb5Zdtv5hRzDlcPyLfT0--vf-Yj1UUcs9l1efcS8W54jrCwBfKGEvPFAMzd0KooIVrtNe2KBzTXtasBFQDRjkxiKapZGSPyV4368JTQr1ypZVFAwKFKEpGp6MMhQ68VE5Z5jNyeC1T40eKcax0MTUQaiAKJqFgEAWTUMjI680X84Fe4y9tjxGmTTskxk4PQF3MqC7mX-qSkZfXIBswJNwdsV2YrZamRBogpFOUGXkygL75VaWQ-E-ojKgdddjpy-6brv2RyLrB30YCnf3_0fln5A6KA6fOqnxO9vrFKrwgt_xl3y4XB-SmmtQHyQ7g_uXq5BeeohEe |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Is+Penicillin+plus+Gentamicin+Synergistic+against+Clinical+Group+B+Streptococcus+isolates%3F%3A+A+in-vitro+Study&rft.jtitle=Frontiers+in+microbiology&rft.au=Corinne+Ruppen&rft.au=Agnese+Lupo&rft.au=Laurent+Decosterd&rft.au=Parham+Sendi&rft.date=2016-10-21&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-302X&rft.volume=7&rft_id=info:doi/10.3389%2Ffmicb.2016.01680&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5dfb748fbadd4939b7c3a32f5a79db59 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-302X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-302X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-302X&client=summon |